Virology News and Research

Latest Virology News and Research

HBV-infected men more likely to develop liver cancer

A team of researchers has identified a novel mutation in the hepatitis B virus (HBV) in Korea that appears only in men and could help explain why HBV-infected men are roughly five times more likely than HBV-infected women to develop liver cancer.

18 Oct 2013

New method to display viral DNA in host cells at single-molecule resolution

The medical, humanitarian and economical impact of viral diseases is devastating to humans and livestock. There are no adequate therapies available against most viral diseases, largely because the mechanisms by which viruses infect cells are poorly known.

17 Oct 2013

Most U.S. adolescents lack antibodies that may help protect against genital herpes, says study

A new study suggests a growing number of U.S. adolescents lack antibodies that may help protect them later in life against an increasingly important cause of genital herpes. Published in The Journal of Infectious Diseases and available online, the findings show that fewer of today's teens have been exposed in their childhood to herpes simplex virus type 1 (HSV-1), a common cause of cold sores, than U.S. adolescents in previous years.

17 Oct 2013

New type of antibiotic kills multidrug-resistant germ common to health care settings

A new type of antibiotic called a PPMO, which works by blocking genes essential for bacterial reproduction, successfully killed a multidrug-resistant germ common to health care settings, UT Southwestern Medical Center researchers report.

16 Oct 2013

Janssen seeks European marketing approval for combination of once-daily darunavir with cobicistat

Janssen-Cilag International NV, today announced it has submitted a Marketing Authorisation Application to the European Medicines Agency seeking approval for a once-daily single tablet fixed-dose antiretroviral combination product containing darunavir, a protease inhibitor developed by Janssen, with cobicistat, a pharmacokinetic enhancer or boosting agent, developed by Gilead Sciences, Inc. for use in combination with other human immunodeficiency virus medicines.

15 Oct 2013

Measles-containing vaccines administered at 12-5 months of age associated with reduced risk of fever, seizures

Children receiving measles-containing vaccines at 12-15 months of age have a lower increased risk of fever and seizures than those who receive them at 16-23 months of age, according to a new Kaiser Permanente study published in JAMA Pediatrics.

15 Oct 2013

Canadian discovery could lead to development of vaccine against Epstein-Barr virus

Development of a vaccine against Epstein-Barr virus has taken a step forward with the Canadian discovery of how EBV infection evades detection by the immune system.

12 Oct 2013

Longer looks: Problems with 'regular insurance;' more TV characters with mental illness; women dying younger

Every week reporter Ankita Rao selects interesting reading from around the Web.

11 Oct 2013

Researchers find ways to identify, isolate HCC progenitor cells before tumors become evident

For the first time, researchers at the University of California, San Diego School of Medicine have isolated and characterized the progenitor cells that eventually give rise to malignant hepatocellular carcinoma tumors - the most common form of liver cancer. The researchers found ways to identify and isolate the HCC progenitor cells long before actual tumors were apparent.

11 Oct 2013

Small interfering RNAs in mammals act as specific antiviral weapons

Many viral infections are nipped in the bud by the innate immune response. This involves specific proteins within the infected cell that recognize the virus and trigger a signalling cascade - the so-called interferon response. This activates a protective mechanism in neighbouring cells and often results in the death of the primarily infected cell.

11 Oct 2013

Adding danoprevir to treatment regimen for hepatitis C patients leads to high rates of remission

The addition of danoprevir to the current treatment regimen for patients with hepatitis C leads to high rates of remission, according to a new article in Gastroenterology, the official journal of the American Gastroenterological Association.

11 Oct 2013

Teva Cutting 5,000 Jobs In Global Restructuring

...

10 Oct 2013

New MERS coronavirus emerged from bats to humans: Research

The newly emerged Middle East respiratory syndrome coronavirus has circulated in bats for a substantial time, before making the species leap to humans, according to research published in BioMed Central's open access publication Virology Journal.

10 Oct 2013

Research on flaviviruses could help in developing effective therapies for persistent infections

We generally do not devote much time to worrying about the problems faced by viruses, although understanding them may provide clues on how to combat diseases.

9 Oct 2013

Researchers recently launched Collaborative Hepatitis Network in Africa

Although it does not receive as much attention as AIDS, hepatitis has long been one of Africa's most serious health problems.

9 Oct 2013

Healthcare providers report unaccompanied teens may not receive required vaccines

Healthcare providers report that older teens often go to the doctor without a parent or guardian, a new survey in the Journal of Adolescent Health reveals—and those teens may not get necessary vaccinations because there's no parent or guardian present to give consent.

9 Oct 2013

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Janssen Pharmaceuticals, Inc. announced today the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc.

9 Oct 2013

Sahlgrenska Academy study finds no traces of viruses in breast cancer and glioblastoma

A major study conducted at the Sahlgrenska Academy has now disproved theories of a viral cause for breast cancer and the brain tumour, glioblastoma. The study, which was based on over seven billion DNA sequences and which is published in Nature Communications, found no genetic traces of viruses in these forms of cancer.

9 Oct 2013

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.

9 Oct 2013

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Boehringer Ingelheim today announced that interim data from its Phase II hepatitis C (HCV) clinical collaboration with Presidio Pharmaceuticals have been accepted for presentation as a late breaker poster at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 1-5 November in Washington, D.C. (1) The poster presentation will be on Monday 4 November.

8 Oct 2013

Virology News and Research

Latest Virology News and Research

HBV-infected men more likely to develop liver cancer

New method to display viral DNA in host cells at single-molecule resolution

Most U.S. adolescents lack antibodies that may help protect against genital herpes, says study

New type of antibiotic kills multidrug-resistant germ common to health care settings

Janssen seeks European marketing approval for combination of once-daily darunavir with cobicistat

Measles-containing vaccines administered at 12-5 months of age associated with reduced risk of fever, seizures

Canadian discovery could lead to development of vaccine against Epstein-Barr virus

Longer looks: Problems with 'regular insurance;' more TV characters with mental illness; women dying younger

Researchers find ways to identify, isolate HCC progenitor cells before tumors become evident

Small interfering RNAs in mammals act as specific antiviral weapons

Adding danoprevir to treatment regimen for hepatitis C patients leads to high rates of remission

Teva Cutting 5,000 Jobs In Global Restructuring

New MERS coronavirus emerged from bats to humans: Research

Research on flaviviruses could help in developing effective therapies for persistent infections

Researchers recently launched Collaborative Hepatitis Network in Africa

Healthcare providers report unaccompanied teens may not receive required vaccines

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Sahlgrenska Academy study finds no traces of viruses in breast cancer and glioblastoma

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics